LYEL

SEC source: 0002150331-26-000003 · form4-10132026_091052.xml · nonDerivative · entry 1

Aguirre Jarrad Mattieu · CIK 0002150331 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,857

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $8.54 to $8.63 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001959742-26-000003 · form4-09102026_110937.xml · nonDerivative · entry 1

Shook David · CIK 0001959742 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,423

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $12.32 to $12.70 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0002150331-26-000002 · form4-09102026_110951.xml · derivative · entry 2

Aguirre Jarrad Mattieu · CIK 0002150331 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,500

Underlying: Common Stock · 47,500 shares

Expires 2036-09-09

F2 · derivative.exercise_date: 12.5% of the option shares will vest on February 28, 2027, with the remaining option shares to vest in equal monthly installments over the following 42 months, subject to the reporting person providing service through the applicable vesting date.

SEC source: 0001866154-26-000006 · form4-08252026_080813.xml · nonDerivative · entry 1

Hill Stephen J. · CIK 0001866154 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,816

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

SEC source: 0001327111-26-000006 · form4-08252026_080833.xml · nonDerivative · entry 1

Seely Lynn · CIK 0001327111 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,899

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

SEC source: 0001907345-26-000006 · form4-08252026_080815.xml · nonDerivative · entry 1

Lee Gary K. · CIK 0001907345 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,220

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

SEC source: 0002095702-26-000005 · form4-08112026_080848.xml · nonDerivative · entry 1

Bulis Veronica Sanchez · CIK 0002095702 · VP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,799

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.20 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001866154-26-000004 · form4-08112026_080811.xml · nonDerivative · entry 1

Hill Stephen J. · CIK 0001866154 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,805

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.27 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001907345-26-000004 · form4-08112026_080834.xml · nonDerivative · entry 1

Lee Gary K. · CIK 0001907345 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,677

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.22 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001327111-26-000004 · form4-08112026_080842.xml · nonDerivative · entry 1

Seely Lynn · CIK 0001327111 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,488

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.22 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001140361-26-029817 · form4.xml · nonDerivative · entry 1

Innovative Cellular Therapeutics Holdings Ltd · CIK 0002095697 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,774,980

F1 · shares: Represents shares of Common Stock transferred by the Reporting Person to Wuxiong, Inc. as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.

F2 · balance_after: Reflects 2,818,980 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 44,000 shares transferred.

SEC source: 0001140361-26-029791 · form4.xml · nonDerivative · entry 1

Innovative Cellular Therapeutics Holdings Ltd · CIK 0002095697 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,818,980

F1 · shares: Represents shares of Common Stock transferred by the Reporting Person to LifeSci Advisors, LLC as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.

F2 · balance_after: Reflects 2,857,480 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 38,500 shares transferred.

SEC source: 0001140361-26-028955 · form4.xml · nonDerivative · entry 1

Innovative Cellular Therapeutics Holdings Ltd · CIK 0002095697 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,857,480

F1 · balance_after: Reflects 2,857,490 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold.

SEC source: 0001140361-26-028846 · form4.xml · nonDerivative · entry 1

Innovative Cellular Therapeutics Holdings Ltd · CIK 0002095697 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,857,490

F1 · balance_after: Reflects 2,857,500 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold.

SEC source: 0001140361-26-027140 · form4.xml · nonDerivative · entry 1

Innovative Cellular Therapeutics Holdings Ltd · CIK 0002095697 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,857,500

F1 · shares: Represents shares of Common Stock transferred by the Reporting Person to Wuxiong, Inc. as broker commission in connection with the Upfront Payment (as such term is defined in the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.

F2 · balance_after: Reflects 2,933,500 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 76,000 shares transferred.

SEC source: 0001140361-26-025796 · form4.xml · nonDerivative · entry 1

Innovative Cellular Therapeutics Holdings Ltd · CIK 0002095697 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,933,500

F1 · shares: Represents shares of Common Stock transferred by the Reporting Person to LifeSci Advisors, LLC as broker commission in connection with the Upfront Payment (as such term is defined in the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.

F2 · balance_after: Reflects 3,000,000 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 66,500 shares transferred. All shares are held directly and registered in the name of the Reporting Person.

SEC source: 0001959742-26-000002 · form4-06112026_080646.xml · nonDerivative · entry 1

Shook David · CIK 0001959742 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,923

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

F2 · balance_after: Includes 1,000 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan.

SEC source: 0001182471-26-000002 · form4-06122026_080603.xml · derivative · entry 1

RIEFLIN WILLIAM JL · CIK 0001182471 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,250

Underlying: Common Stock · 9,250 shares

Expires 2036-06-09

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

SEC source: 0001619929-26-000004 · form4-06122026_080608.xml · derivative · entry 1

NABEL ELIZABETH G · CIK 0001619929 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,250

Underlying: Common Stock · 9,250 shares

Expires 2036-06-09

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

SEC source: 0001439368-26-000002 · form4-06122026_080637.xml · derivative · entry 2

Ramachandra Sumant · CIK 0001439368 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,250

Underlying: Common Stock · 9,250 shares

Expires 2036-06-09

F3 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

SEC source: 0001591178-26-000002 · form4-06122026_080656.xml · derivative · entry 3

Klausner Richard · CIK 0001591178 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,250

Underlying: Common Stock · 9,250 shares

Expires 2036-06-09

F3 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

SEC source: 0001213029-26-000007 · form4-06122026_080623.xml · derivative · entry 2

BRAWLEY OTIS W · CIK 0001213029 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,250

Underlying: Common Stock · 9,250 shares

Expires 2036-06-09

F2 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

SEC source: 0001411874-26-000002 · form4-06122026_080616.xml · derivative · entry 3

FRIEDMAN CATHY · CIK 0001411874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,250

Underlying: Common Stock · 9,250 shares

Expires 2036-06-09

F4 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

SEC source: 0001887762-26-000002 · form4-06122026_080602.xml · derivative · entry 1

Bachleda Mark · CIK 0001887762 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,250

Underlying: Common Stock · 9,250 shares

Expires 2036-06-09

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

SEC source: 0002095702-26-000004 · form4-06152026_100616.xml · nonDerivative · entry 1

Bulis Veronica Sanchez · CIK 0002095702 · VP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,420

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001866154-26-000003 · form4-06152026_100659.xml · nonDerivative · entry 1

Hill Stephen J. · CIK 0001866154 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,894

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F3 · balance_after: Includes 188 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan.

SEC source: 0001327111-26-000003 · form4-06152026_100612.xml · nonDerivative · entry 1

Seely Lynn · CIK 0001327111 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,878

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.15 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001907345-26-000003 · form4-06152026_100619.xml · nonDerivative · entry 1

Lee Gary K. · CIK 0001907345 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,808

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F3 · balance_after: Includes 1,000 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan.

SEC source: 0001808821-26-000006 · form4-03162026_110321.xml · derivative · entry 1

Shah Smital · CIK 0001808821 · Chief Fin. and Bus. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 140,000 shares

Expires 2036-03-08

F1 · derivative.exercise_date: 25% of the option shares will vest on March 9, 2027, with the remaining option shares to vest in equal monthly installments over the following 36 months, subject to the reporting person providing service through the applicable vesting date.

SEC source: 0001012975-26-000234 · form4.xml · nonDerivative · entry 1

ARCH Venture Fund XIII, L.P. · CIK 0002006772 · 10% owner

ARCH Venture Partners XIII, L.P. · CIK 0002016083 · 10% owner

ARCH Venture Partners XIII, LLC · CIK 0002016082 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

Burow Kristina · CIK 0001569248 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

BERNS PAUL L · CIK 0001202769 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,426,528

F1 · ownership.nature: These shares are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001012975-26-000235 · form4.xml · nonDerivative · entry 1

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,426,528

F1 · ownership.nature: These shares are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001866154-26-000002 · form4-02132026_010228.xml · nonDerivative · entry 1

Hill Stephen J. · CIK 0001866154 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,795

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units.

F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.7850 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001907345-26-000002 · form4-02132026_010253.xml · nonDerivative · entry 1

Lee Gary K. · CIK 0001907345 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,938

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units.

F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.6305 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001327111-26-000002 · form4-02132026_010246.xml · nonDerivative · entry 1

Seely Lynn · CIK 0001327111 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,266

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units.

F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.7850 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0002095702-26-000002 · form4-02122026_020223.xml · nonDerivative · entry 2

Bulis Veronica Sanchez · CIK 0002095702 · VP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,637

F2 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

SEC source: 0002095702-26-000002 · form4-02122026_020223.xml · nonDerivative · entry 1

Bulis Veronica Sanchez · CIK 0002095702 · VP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,891

F1 · shares: Represents restricted stock units granted under the Issuer's 2021 Equity Incentive Plan. 12.5% of the total number of restricted stock units will vest on August 9, 2026, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.

SEC source: 0001959742-26-000001 · form4-02122026_010247.xml · derivative · entry 2

Shook David · CIK 0001959742 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-02-09

F1 · derivative.exercise_date: Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.

SEC source: 0001866154-26-000001 · form4-02122026_020218.xml · derivative · entry 3

Hill Stephen J. · CIK 0001866154 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2036-02-09

F4 · derivative.exercise_date: Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.

SEC source: 0001866154-26-000001 · form4-02122026_020218.xml · nonDerivative · entry 2

Hill Stephen J. · CIK 0001866154 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,031

F3 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

SEC source: 0001907345-26-000001 · form4-02122026_020216.xml · derivative · entry 3

Lee Gary K. · CIK 0001907345 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-02-09

F4 · derivative.exercise_date: Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.

SEC source: 0001907345-26-000001 · form4-02122026_020216.xml · nonDerivative · entry 2

Lee Gary K. · CIK 0001907345 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,609

F3 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

SEC source: 0001327111-26-000001 · form4-02122026_020200.xml · derivative · entry 3

Seely Lynn · CIK 0001327111 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,000

Underlying: Common Stock · 155,000 shares

Expires 2036-02-09

F3 · derivative.exercise_date: Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one forty-eighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.

SEC source: 0001327111-26-000001 · form4-02122026_020200.xml · nonDerivative · entry 2

Seely Lynn · CIK 0001327111 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,721

F2 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

SEC source: 0001771329-26-000001 · form4-02122026_020247.xml · derivative · entry 1

Meltz Mark A · CIK 0001771329 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-02-09

F1 · derivative.exercise_date: Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.

SEC source: 0001866154-26-000001 · form4-02122026_020218.xml · nonDerivative · entry 1

Hill Stephen J. · CIK 0001866154 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,140

F1 · shares: Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date.

F2 · balance_after: Includes 390 shares acquired on November 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.

SEC source: 0001907345-26-000001 · form4-02122026_020216.xml · nonDerivative · entry 1

Lee Gary K. · CIK 0001907345 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,756

F1 · shares: Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date.

F2 · balance_after: Includes 390 shares acquired on November 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.

SEC source: 0001327111-26-000001 · form4-02122026_020200.xml · nonDerivative · entry 1

Seely Lynn · CIK 0001327111 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,159

F1 · shares: Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 20,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date.

SEC source: 0002095702-26-000001 · form4-01062026_090153.xml · nonDerivative · entry 2

Bulis Veronica Sanchez · CIK 0002095702 · VP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,141

SEC source: 0002095702-26-000001 · form4-01062026_090153.xml · nonDerivative · entry 1

Bulis Veronica Sanchez · CIK 0002095702 · VP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,077

F1 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $38.6643 to $38.6751 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0002095702-25-000003 · form4-11132025_011155.xml · nonDerivative · entry 1

Bulis Veronica Sanchez · CIK 0002095702 · VP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,213

F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $16.08 to $16.11 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.